Hepion Pharmaceuticals, Inc. (HEPA)

OTCMKTS · Delayed Price · Currency is USD
0.0400
-0.0010 (-2.44%)
At close: Feb 27, 2026
-99.49%
Market Cap 464.81K
Revenue (ttm) n/a
Net Income (ttm) -9.17M
Shares Out 11.62M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,340
Average Volume 8,080
Open 0.0410
Previous Close 0.0410
Day's Range 0.0400 - 0.0434
52-Week Range 0.0330 - 7.8000
Beta 2.00
RSI 44.33
Earnings Date Mar 27, 2026

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The compan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 22
Stock Exchange OTCMKTS
Ticker Symbol HEPA
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.